Arbutus Biopharma Logo
Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update
06 nov. 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019...
Arbutus Biopharma Logo
Arbutus to Report Third Quarter 2019 Financial Results
30 oct. 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its...
Arbutus Biopharma Logo
Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B
03 oct. 2019 16h05 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue...
Arbutus Biopharma Logo
Arbutus to Participate in Upcoming Investor Conferences
26 sept. 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the...
Arbutus Biopharma Logo
Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors
20 août 2019 16h05 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that...
Arbutus Biopharma Logo
Arbutus to Participate at Wedbush PacGrow Healthcare Conference
06 août 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus Biopharma Logo
Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
05 août 2019 07h30 HE | Arbutus Biopharma Corporation
- Appointed William Collier, with decades of leadership experience in antivirals, President & CEO - Announced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent...
Arbutus Biopharma Logo
Arbutus to Report Second Quarter 2019 Financial Results
29 juil. 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., July 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it...
Arbutus Biopharma Logo
Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B
15 juil. 2019 16h05 HE | Arbutus Biopharma Corporation
Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET ...
Arbutus Biopharma Logo
Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS
02 juil. 2019 16h01 HE | Arbutus Biopharma Corporation
 - Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics  - Runway extended with non-dilutive capital WARMINSTER, Pa., July 02,...